Dina, E., Nasser, M., Sarah, E., Mahmoud, A., Islam, M., Waleed, E., Muhammad, D. (2020). Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy. Medical Journal of Viral Hepatitis, 4.2(2), 69-73. doi: 10.21608/mjvh.2020.80655
Elhammady Dina; Mousa Nasser; Eissa Sarah; Awad Mahmoud; Mohamed Islam; Eldars Waleed; Diasty Muhammad. "Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy". Medical Journal of Viral Hepatitis, 4.2, 2, 2020, 69-73. doi: 10.21608/mjvh.2020.80655
Dina, E., Nasser, M., Sarah, E., Mahmoud, A., Islam, M., Waleed, E., Muhammad, D. (2020). 'Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy', Medical Journal of Viral Hepatitis, 4.2(2), pp. 69-73. doi: 10.21608/mjvh.2020.80655
Dina, E., Nasser, M., Sarah, E., Mahmoud, A., Islam, M., Waleed, E., Muhammad, D. Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy. Medical Journal of Viral Hepatitis, 2020; 4.2(2): 69-73. doi: 10.21608/mjvh.2020.80655
Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy
1Tropical Medicine dept., Faculty of Medicine, Mansoura Univ., Mansoura, Egypt
2Tropical Medicine dept, Faculty of Medicine, Mansoura Univ., Egypt.
3Internal Medicine dept., Faculty of Medicine, Mansoura Univ., Mansoura, Egypt
4Medical Microbiology and Immunology dept., Faculty of Medicine, Mansoura Univ, Mansoura, Egypt
Abstract
Background and study aim. The introduction of directacting antiviral agents (DAAs) has increased sustained virologic response (SVR) rates in patients with chronic hepatitis C infection (CHC). The aim of this study is to evaluate the efficacy of DAAs in treatment of Egyptian patients with CHC, and to determine the parameters associated with non-response to DAAs Patients and methods. This study included 200 treatment-naïve chronic hepatitis C patients who were divided into two groups and treated according to the Egyptian National Treatment Program for Hepatitis C Virus. Group 1 consisted of 100 easy-totreat patients who were administered sofosbuvir 400 mg daily/daclatasvir 60 mg daily for 3 months, while group 2 included 100 difficult-to-treat patients treated by Sofosbuvir 400 mg/ daclatasvir 60 mg /ribavirin daily for 3 months Results. The overall patient sustained virologic response (SVR) in the present study was 93.5% (187/200). SVR in group 1 was 100%, while group 2 showed SVR of 87% (87/100). Comparison between patients with and without SVR revealed no statistically significant differences regarding age and sex distribution, serum albumin, bilirubin, transaminases level, INR and platelets count. However, patients who were non-responders had signi-ficantly higher pre-treatment alpha fetoprotein (AFP) levels than responders Conclusions. Treatment of CHC pati-ents with DAAs is associated with higher sustained virologic response, particularly in easy-totreat patients. AFP level may aid in prediction of non-responders to DAAs
View on SCiNiTO
Top